Research & Development
NeuroSense, NeuraLight partner on biomarkers for ALS
NeuraLight uses proprietary computer vision and learning algorithms to extract coulometric markers from facial videos captured with a webcam. NeuroSense is conducting the phase IIB PARADIGM trial evaluating the efficacy of NeuroSense's lead combination drug candidate, PrimeC, in treating ALS.
July 27, 2022
Arlington Scientific, Brain Chemistry Labs ink collaboration
Only 8% to 10% of ALS cases are genetic, according to Brain Chemistry Labs. In 90% to 92% of cases, environmental risk factors may play a role. BMAA is often present in cyanobacterial blooms in water and is suspected to be the top environmental factor contributing to ALS, the company said.
March 20, 2022
Page 1 of 1